NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Price Target & More

$79.40 +1.22 (+1.56 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$79.40
Today's Range$77.01 - $80.42
52-Week Range$41.76 - $92.98
Volume600,025 shs
Average Volume788,544 shs
Market Capitalization$7.14 billion
P/E Ratio-49.01
Dividend YieldN/A
Beta0.29

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Debt-to-Equity Ratio0.99%
Current Ratio10.20%
Quick Ratio10.20%

Price-To-Earnings

Trailing P/E Ratio-49.01
Forward P/E Ratio-345.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$161.63 million
Price / Sales44.15
Cash FlowN/A
Price / CashN/A
Book Value$4.21 per share
Price / Book18.86

Profitability

EPS (Most Recent Fiscal Year)($1.62)
Net Income$-142,540,000.00
Net MarginsN/A
Return on Equity-43.46%
Return on Assets-21.65%

Miscellaneous

Employees400
Outstanding Shares89,880,000

How to Become a New Pot Stock Millionaire

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences (NASDAQ:NBIX) released its quarterly earnings data on Tuesday, February, 13th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.18 by $0.11. The business had revenue of $94.52 million for the quarter, compared to analysts' expectations of $94 million. During the same quarter in the previous year, the company posted ($0.51) EPS. View Neurocrine Biosciences' Earnings History.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Neurocrine Biosciences.

What price target have analysts set for NBIX?

13 Wall Street analysts have issued 12-month price objectives for Neurocrine Biosciences' shares. Their predictions range from $65.00 to $113.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $95.2308 in the next twelve months. View Analyst Ratings for Neurocrine Biosciences.

Who are some of Neurocrine Biosciences' key competitors?

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 60)
  • Dr. Haig P. Bozigian Ph.D., Chief Devel. Officer (Age 60)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 53)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 61)
  • Mr. Matthew C. Abernethy, CFO & Principal Accounting Officer

Has Neurocrine Biosciences been receiving favorable news coverage?

Headlines about NBIX stock have trended somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neurocrine Biosciences earned a coverage optimism score of 0.14 on Accern's scale. They also gave media coverage about the company an impact score of 45.65 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $79.40.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $7.14 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NBIX)

Community Ranking:  4.1 out of 5 (star star star star)
Outperform Votes:  622 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  755
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neurocrine Biosciences (NASDAQ:NBIX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Neurocrine Biosciences in the last 12 months. Their average twelve-month price target is $95.2308, suggesting that the stock has a possible upside of 19.94%. The high price target for NBIX is $113.00 and the low price target for NBIX is $65.00. There are currently 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.94
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $95.2308$95.2308$82.3125$68.8125
Price Target Upside: 19.94% upside12.26% upside1.16% upside10.42% upside

Neurocrine Biosciences (NASDAQ:NBIX) Consensus Price Target History

Price Target History for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2018OppenheimerSet Price TargetBuy$110.00HighView Rating Details
3/14/2018Piper JaffrayReiterated RatingOverweight$113.00MediumView Rating Details
2/22/2018Needham & Company LLCReiterated RatingBuy -> Buy$95.00 -> $110.00LowView Rating Details
2/20/2018Leerink SwannBoost Price TargetOutperform$90.00 -> $96.00MediumView Rating Details
2/14/2018Deutsche BankBoost Price TargetBuy$97.00MediumView Rating Details
2/14/2018JPMorgan ChaseBoost Price TargetOverweight -> Overweight$79.00 -> $100.00HighView Rating Details
2/14/2018BarclaysReiterated RatingOverweight$100.00HighView Rating Details
1/5/2018Jefferies GroupBoost Price TargetBuy$105.00MediumView Rating Details
11/3/2017Robert W. BairdReiterated RatingBuy$84.00N/AView Rating Details
11/2/2017BMO Capital MarketsBoost Price TargetPositive -> Outperform$83.00 -> $109.00N/AView Rating Details
11/2/2017CitigroupReiterated RatingBuy$79.00N/AView Rating Details
8/9/2017CowenReiterated RatingOutperform$60.00 -> $65.00MediumView Rating Details
5/15/2017Bank of AmericaReiterated RatingBuy$70.00MediumView Rating Details
3/7/2017Cantor FitzgeraldReiterated RatingOverweight$80.00N/AView Rating Details
2/16/2017HC WainwrightBoost Price TargetPositive$80.00 -> $100.00N/AView Rating Details
2/10/2017ICAPReiterated RatingOutperform$55.00N/AView Rating Details
1/27/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Earnings History and Estimates Chart

Earnings by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.28)($0.22)($0.26)
Q2 20183($0.19)$0.33$0.12
Q3 20183($0.13)$0.01($0.05)
Q4 20183($0.06)$0.43$0.18

Neurocrine Biosciences (NASDAQ NBIX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.21)N/AView Earnings Details
2/13/2018Q4 2017$0.18$0.07$94.00 million$94.52 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.49)($0.13)$29.38 million$60.77 millionViewN/AView Earnings Details
8/3/2017Q2 17($0.67)($0.68)$0.61 million$6.34 millionViewListenView Earnings Details
5/9/2017Q1 17($0.67)($0.90)$3.00 millionViewListenView Earnings Details
2/14/2017Q416($0.55)($0.51)$4.55 millionViewListenView Earnings Details
11/2/2016Q316($0.57)($0.43)ViewN/AView Earnings Details
8/3/2016Q2 2016($0.50)($0.46)ViewN/AView Earnings Details
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details
7/29/2015Q2($0.2860)($0.28)$0.41 millionViewListenView Earnings Details
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details
4/30/2014Q114($0.19)($0.17)$0.78 millionViewN/AView Earnings Details
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details
5/2/2012($0.01)ViewN/AView Earnings Details
2/8/2012Q4 2011$0.01$0.02ViewN/AView Earnings Details
10/31/2011$0.19$0.56ViewN/AView Earnings Details
7/28/2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011$0.05$0.05ViewN/AView Earnings Details
2/10/2011$0.04$0.05ViewN/AView Earnings Details
10/28/2010Q3 2010$0.05$0.06ViewN/AView Earnings Details
7/28/2010Q2 2010($0.17)($0.09)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.24)($0.20)ViewN/AView Earnings Details
2/3/2010Q4 2009($0.28)($0.22)ViewN/AView Earnings Details
10/28/2009Q3 2009($0.35)($0.21)ViewN/AView Earnings Details
7/29/2009Q2 2009($0.41)($0.37)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.38)($0.38)ViewN/AView Earnings Details
2/3/2009Q4 2008($0.47)($0.75)ViewN/AView Earnings Details
10/28/2008Q3 2008($0.52)($0.46)ViewN/AView Earnings Details
7/30/2008Q2 2008($0.52)($0.55)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.54)($0.55)ViewN/AView Earnings Details
2/5/2008Q4 2007($0.84)($0.71)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Neurocrine Biosciences (NASDAQ:NBIX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Neurocrine Biosciences (NASDAQ NBIX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%
Insider Trading History for Neurocrine Biosciences (NASDAQ:NBIX)
Insider Trading History for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ NBIX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/5/2018Haig P BozigianInsiderSell75,873$90.00$6,828,570.0018,041View SEC Filing  
2/15/2018Gary A LyonsDirectorSell5,000$84.67$423,350.00View SEC Filing  
2/12/2018Dimitri E GrigoriadisInsiderSell86,368$78.32$6,764,341.76154,717View SEC Filing  
2/9/2018Dimitri E GrigoriadisInsiderSell71,775$77.98$5,597,014.50154,717View SEC Filing  
2/6/2018Kevin Charles GormanCEOSell105,983$80.25$8,505,135.75339,482View SEC Filing  
2/5/2018Gary A LyonsDirectorSell5,000$83.08$415,400.00267,066View SEC Filing  
2/5/2018Haig P BozigianInsiderSell2,262$83.10$187,972.2076,950View SEC Filing  
1/24/2018William H RastetterDirectorSell9,500$90.00$855,000.0034,250View SEC Filing  
1/16/2018Haig P BozigianInsiderSell1,625$79.12$128,570.00View SEC Filing  
1/16/2018Kevin Charles GormanCEOSell3,750$78.89$295,837.50View SEC Filing  
1/3/2018Darin LippoldtInsiderSell1,979$79.36$157,053.44View SEC Filing  
12/28/2017Darin LippoldtInsiderSell15,237$75.00$1,142,775.00View SEC Filing  
12/28/2017Darin LippoldtInsiderSell15,237$75.00$1,142,775.0028,394View SEC Filing  
12/8/2017Darin LippoldtInsiderSell2,955$75.00$221,625.0016,112View SEC Filing  
12/4/2017Darin LippoldtInsiderSell6,279$75.04$471,176.1619,436View SEC Filing  
12/1/2017Gary A LyonsDirectorSell10,000$72.92$729,200.00272,066View SEC Filing  
11/15/2017Darin LippoldtInsiderSell9,900$73.05$723,195.00View SEC Filing  
11/8/2017Dimitri E GrigoriadisInsiderSell30,000$74.58$2,237,400.0077,691View SEC Filing  
11/2/2017Kyle GanoInsiderSell24,818$71.05$1,763,318.9084,596View SEC Filing  
10/2/2017Christopher Flint ObrienInsiderSell6,925$61.04$422,702.0055,898View SEC Filing  
9/6/2017Haig P BozigianInsiderSell26,250$60.00$1,575,000.00144,601View SEC Filing  
9/5/2017Christopher Flint ObrienInsiderSell52,817$57.50$3,036,977.50101,790View SEC Filing  
8/9/2017Dimitri E GrigoriadisInsiderSell15,354$55.00$844,470.00123,045View SEC Filing  
8/4/2017Haig P BozigianInsiderSell22,500$50.00$1,125,000.00154,601View SEC Filing  
7/27/2017Christopher Flint ObrienInsiderSell8,734$50.00$436,700.0057,707View SEC Filing  
5/23/2017Dimitri E GrigoriadisInsiderSell10,000$53.39$533,900.00107,691View SEC Filing  
5/19/2017Malcolm Lloyd-SmithInsiderSell9,960$53.63$534,154.8017,997View SEC Filing  
5/5/2017Corinne H NevinnyDirectorSell5,000$53.98$269,900.0034,603View SEC Filing  
5/2/2017Dimitri E GrigoriadisInsiderSell10,000$55.00$550,000.00117,691View SEC Filing  
5/2/2017Kevin Charles GormanCEOSell21,739$53.23$1,157,166.97354,346View SEC Filing  
5/1/2017Kyle GanoInsiderSell15,000$54.00$810,000.0088,246View SEC Filing  
4/12/2017Haig P BozigianInsiderSell13,065$50.42$658,737.30129,805View SEC Filing  
4/12/2017Kevin Charles GormanCEOSell19,596$50.42$988,030.32332,913View SEC Filing  
2/7/2017Malcolm Lloyd-SmithInsiderSell116$44.61$5,174.76View SEC Filing  
2/6/2017Dimitri E GrigoriadisInsiderSell727$43.13$31,355.51115,756View SEC Filing  
2/6/2017Kevin Charles GormanCEOSell3,010$43.18$129,971.80250,542View SEC Filing  
2/6/2017Timothy P CoughlinCFOSell963$43.14$41,543.82137,961View SEC Filing  
2/3/2017Christopher Flint ObrienInsiderSell1,500$42.50$63,750.0035,044View SEC Filing  
2/3/2017Kevin Charles GormanCEOSell3,125$42.55$132,968.75247,802View SEC Filing  
2/1/2017William H RastetterDirectorSell10,750$42.28$454,510.0025,000View SEC Filing  
1/17/2017Haig P BozigianInsiderSell1,625$40.63$66,023.75114,704View SEC Filing  
1/17/2017Kevin Charles GormanCEOSell3,750$40.65$152,437.50244,677View SEC Filing  
1/17/2017Timothy P CoughlinCFOSell1,750$40.65$71,137.50134,824View SEC Filing  
1/10/2017Christopher Flint ObrienInsiderSell1,750$43.35$75,862.5031,794View SEC Filing  
1/10/2017Kevin Charles GormanCEOSell3,750$43.28$162,300.00240,927View SEC Filing  
11/15/2016Christopher Flint ObrienInsiderSell25,000$52.84$1,321,000.0030,044View SEC Filing  
9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.009,000View SEC Filing  
8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.0055,044View SEC Filing  
8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.0025,555View SEC Filing  
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.0015,464View SEC Filing  
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.0080,044View SEC Filing  
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.4057,788View SEC Filing  
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00105,044View SEC Filing  
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75111,454View SEC Filing  
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00228,077View SEC Filing  
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00131,374View SEC Filing  
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25110,079View SEC Filing  
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00224,952View SEC Filing  
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50129,874View SEC Filing  
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25108,454View SEC Filing  
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50221,202View SEC Filing  
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50128,124View SEC Filing  
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00105,308View SEC Filing  
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00106,829View SEC Filing  
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00217,452View SEC Filing  
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00252,066View SEC Filing  
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.0077,058View SEC Filing  
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.0096,544View SEC Filing  
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50180,952View SEC Filing  
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.0097,874View SEC Filing  
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.0075,433View SEC Filing  
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00177,202View SEC Filing  
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.0096,124View SEC Filing  
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.0022,488View SEC Filing  
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.0094,794View SEC Filing  
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.9676,954View SEC Filing  
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.7596,124View SEC Filing  
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.701,000View SEC Filing  
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.0076,954View SEC Filing  
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.3596,124View SEC Filing  
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Neurocrine Biosciences (NASDAQ NBIX) News Headlines

Source:
DateHeadline
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual ...Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual ...
www.prnewswire.com - April 19 at 5:15 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential ...SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential ...
www.prnewswire.com - April 19 at 5:15 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 19 at 8:42 AM
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual MeetingNeurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 18 at 5:22 PM
 Brokerages Anticipate Neurocrine Biosciences (NBIX) Will Announce Quarterly Sales of $65.97 Million Brokerages Anticipate Neurocrine Biosciences (NBIX) Will Announce Quarterly Sales of $65.97 Million
www.americanbankingnews.com - April 17 at 2:33 AM
Neurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.32 Per ShareNeurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - April 15 at 7:17 PM
Oppenheimer Comments on Neurocrine Biosciences Q2 2018 Earnings (NBIX)Oppenheimer Comments on Neurocrine Biosciences' Q2 2018 Earnings (NBIX)
www.americanbankingnews.com - April 13 at 8:51 AM
Ingrezza: Boosting Neurocrine’s Top LineIngrezza: Boosting Neurocrine’s Top Line
finance.yahoo.com - April 12 at 5:10 PM
Neurocrine Biosciences (NBIX) Receives "Outperform" Rating from CowenNeurocrine Biosciences (NBIX) Receives "Outperform" Rating from Cowen
www.americanbankingnews.com - April 11 at 11:23 PM
Neurocrine Biosciences (NBIX) Upgraded by BidaskClub to "Buy"Neurocrine Biosciences (NBIX) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 11 at 8:59 PM
Neurocrine Biosciences (NBIX) Given a $110.00 Price Target by Oppenheimer AnalystsNeurocrine Biosciences (NBIX) Given a $110.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - April 10 at 3:29 PM
AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated PainAbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain
www.nasdaq.com - April 10 at 9:01 AM
A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund StarA Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star
finance.yahoo.com - April 10 at 9:01 AM
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated PainAbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
finance.yahoo.com - April 10 at 9:01 AM
FDA needs more time to review AbbVie, Neurocrines uterine pain drugFDA needs more time to review AbbVie, Neurocrine's uterine pain drug
finance.yahoo.com - April 10 at 9:01 AM
FDA extends review for AbbVie, Neurocrines uterine pain drugFDA extends review for AbbVie, Neurocrine's uterine pain drug
finance.yahoo.com - April 10 at 9:01 AM
Neurocrine Biosciences (NBIX) Given "Buy" Rating at Piper JaffrayNeurocrine Biosciences (NBIX) Given "Buy" Rating at Piper Jaffray
www.americanbankingnews.com - April 5 at 12:39 PM
Neurocrine Biosciences (NBIX) Downgraded by BidaskClubNeurocrine Biosciences (NBIX) Downgraded by BidaskClub
www.americanbankingnews.com - April 4 at 9:30 AM
Neurocrine Biosciences (NBIX) Rating Increased to Buy at ValuEngineNeurocrine Biosciences (NBIX) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 11:38 AM
Neurocrine Biosciences (NBIX) Stock Rating Reaffirmed by CitigroupNeurocrine Biosciences (NBIX) Stock Rating Reaffirmed by Citigroup
www.americanbankingnews.com - April 2 at 12:30 AM
Deutsche Bank Reiterates "Buy" Rating for Neurocrine Biosciences (NBIX)Deutsche Bank Reiterates "Buy" Rating for Neurocrine Biosciences (NBIX)
www.americanbankingnews.com - April 1 at 11:24 PM
Zacks: Brokerages Anticipate Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $66.03 MillionZacks: Brokerages Anticipate Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $66.03 Million
www.americanbankingnews.com - March 31 at 1:56 AM
Neurocrine Biosciences, Inc. (NBIX) Given Consensus Recommendation of "Buy" by BrokeragesNeurocrine Biosciences, Inc. (NBIX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 31 at 1:36 AM
Neurocrine Biosciences (NBIX) Upgraded by BidaskClub to BuyNeurocrine Biosciences (NBIX) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 30 at 5:40 PM
 Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Earnings of -$0.32 Per Share Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - March 29 at 11:26 PM
Neurocrine Biosciences (NBIX) Given a $95.00 Price Target at OppenheimerNeurocrine Biosciences (NBIX) Given a $95.00 Price Target at Oppenheimer
www.americanbankingnews.com - March 28 at 3:48 PM
Needham & Company LLC Raises Neurocrine Biosciences (NBIX) Price Target to $95.00Needham & Company LLC Raises Neurocrine Biosciences (NBIX) Price Target to $95.00
www.americanbankingnews.com - March 28 at 2:42 PM
Neurocrine Biosciences (NBIX) Downgraded by BidaskClub to "Buy"Neurocrine Biosciences (NBIX) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - March 24 at 1:17 PM
Neurocrine Biosciences (NBIX) Receives "Buy" Rating from OppenheimerNeurocrine Biosciences (NBIX) Receives "Buy" Rating from Oppenheimer
www.americanbankingnews.com - March 22 at 10:54 PM
Loss-Making Neurocrine Biosciences Inc (NASDAQ:NBIX) Expected To BreakevenLoss-Making Neurocrine Biosciences Inc (NASDAQ:NBIX) Expected To Breakeven
finance.yahoo.com - March 20 at 8:58 AM
Neurocrine Biosciences, Inc. (NBIX) Expected to Post Q4 2018 Earnings of $0.43 Per ShareNeurocrine Biosciences, Inc. (NBIX) Expected to Post Q4 2018 Earnings of $0.43 Per Share
www.americanbankingnews.com - March 16 at 12:36 PM
FY2019 EPS Estimates for Neurocrine Biosciences, Inc. Lowered by Analyst (NBIX)FY2019 EPS Estimates for Neurocrine Biosciences, Inc. Lowered by Analyst (NBIX)
www.americanbankingnews.com - March 15 at 12:42 PM
Neurocrine Biosciences (NBIX) Rating Reiterated by Piper Jaffray CompaniesNeurocrine Biosciences (NBIX) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - March 15 at 12:58 AM
Is This AbbVies Next Blockbuster Drug?Is This AbbVie's Next Blockbuster Drug?
www.msn.com - March 14 at 6:34 PM
AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine FibroidsAbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
www.prnewswire.com - March 13 at 8:55 AM
Zacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) to Announce -$0.32 Earnings Per ShareZacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) to Announce -$0.32 Earnings Per Share
www.americanbankingnews.com - March 12 at 9:13 PM
Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 75,873 Shares of StockInsider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 75,873 Shares of Stock
www.americanbankingnews.com - March 7 at 6:48 PM
Neurocrine Biosciences to Present at Upcoming Healthcare ConferencesNeurocrine Biosciences to Present at Upcoming Healthcare Conferences
finance.yahoo.com - March 7 at 6:01 PM
Allianz Asset Management GmbH Boosts Stake in Neurocrine Biosciences, Inc. (NBIX)Allianz Asset Management GmbH Boosts Stake in Neurocrine Biosciences, Inc. (NBIX)
www.americanbankingnews.com - March 6 at 4:16 AM
Neurocrine Biosciences, Inc. (NBIX) Receives Consensus Recommendation of "Buy" from AnalystsNeurocrine Biosciences, Inc. (NBIX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 6 at 1:36 AM
Neurocrine Biosciences, Inc. (NBIX) Shares Sold by Sectoral Asset Management IncNeurocrine Biosciences, Inc. (NBIX) Shares Sold by Sectoral Asset Management Inc
www.americanbankingnews.com - March 5 at 3:35 PM
20,000 Shares in Neurocrine Biosciences, Inc. (NBIX) Purchased by Eaton Vance Management20,000 Shares in Neurocrine Biosciences, Inc. (NBIX) Purchased by Eaton Vance Management
www.americanbankingnews.com - March 5 at 10:08 AM
Schroder Investment Management Group Lowers Position in Neurocrine Biosciences, Inc. (NBIX)Schroder Investment Management Group Lowers Position in Neurocrine Biosciences, Inc. (NBIX)
www.americanbankingnews.com - March 5 at 9:02 AM
Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Mallinckrodt, Momenta Pharma, Mylan, and Neurocrine BiosciencesQuotidian Technical Highlights on Selected Generic Drugs Stocks -- Mallinckrodt, Momenta Pharma, Mylan, and Neurocrine Biosciences
www.bizjournals.com - March 5 at 8:45 AM
Emory University Sells 5,537 Shares of Neurocrine Biosciences, Inc. (NBIX)Emory University Sells 5,537 Shares of Neurocrine Biosciences, Inc. (NBIX)
www.americanbankingnews.com - March 4 at 2:59 PM
Neurocrine Biosciences, Inc. (NBIX) Holdings Decreased by Rhumbline AdvisersNeurocrine Biosciences, Inc. (NBIX) Holdings Decreased by Rhumbline Advisers
www.americanbankingnews.com - March 4 at 10:30 AM
UBS Asset Management Americas Inc. Sells 54,520 Shares of Neurocrine Biosciences, Inc. (NBIX)UBS Asset Management Americas Inc. Sells 54,520 Shares of Neurocrine Biosciences, Inc. (NBIX)
www.americanbankingnews.com - February 28 at 5:37 PM
Bank of New York Mellon Corp Has $115.27 Million Holdings in Neurocrine Biosciences, Inc. (NBIX)Bank of New York Mellon Corp Has $115.27 Million Holdings in Neurocrine Biosciences, Inc. (NBIX)
www.americanbankingnews.com - February 27 at 4:42 AM
OppenheimerFunds Inc. Acquires 226,127 Shares of Neurocrine Biosciences, Inc. (NBIX)OppenheimerFunds Inc. Acquires 226,127 Shares of Neurocrine Biosciences, Inc. (NBIX)
www.americanbankingnews.com - February 26 at 1:48 PM
FY2021 EPS Estimates for Neurocrine Biosciences, Inc. (NBIX) Raised by AnalystFY2021 EPS Estimates for Neurocrine Biosciences, Inc. (NBIX) Raised by Analyst
www.americanbankingnews.com - February 26 at 10:08 AM

SEC Filings

Neurocrine Biosciences (NASDAQ:NBIX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neurocrine Biosciences (NASDAQ:NBIX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neurocrine Biosciences (NASDAQ NBIX) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.